SAN FRANCISCO – Five noteworthy studies exploring new approaches in the treatment and management of liver, esophageal, colorectal, and colon cancers will be presented at the 2019 Gastrointestinal Cancers Symposium, taking place January 17-19, 2019 at the Moscone West Building in San Francisco, California.

Experts in gastrointestinal cancers are available to comment on the studies below.

**Abstract 5:** Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.

Rapid Abstract Session A
Thursday, January 17, 2019: 1:00-1:10 p.m. PT
The Moscone West Building, Level 2, Ballroom
Hirva Mamdani, MD
Indiana University
Bloomington, Indiana

**Abstract 350:** Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions.
Poster Session B
Friday, January 18, 2019: 11:30 a.m. - 1:00 p.m. PT
Friday, January 18, 2019, 5:30-6:30 p.m. PT
The Moscone West Building, Level 1, West Hall

Ashwathy Susan Mathew, DNB, MBBS, MD
Princess Margaret Cancer Centre
Department of Radiation Oncology
Ontario, Canada

Abstract 480: A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

Oral Abstract Session C
Saturday, January 19, 2019: 10:45-10:55 p.m. PT
The Moscone West Building, Level 2, Ballroom

Carl Christoph Schimanski, MD, PhD
Klinikum Darmstadt GmbH and Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Germany

Abstract 482: Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial.

Oral Abstract Session C
Saturday, January 19, 2019: 11:20-11:30 a.m. PT
The Moscone West Building, Level 2, Ballroom

Charlotte Klaver, MD, BA
University of Amsterdam
Amsterdam, Netherlands

Abstract 484: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.

Rapid Abstract Session C
Saturday, January 19, 2019: 7:00-7:10 a.m. PT
The Moscone West Building, Level 2, Ballroom

Takao Takahashi, MD, PhD
Department of Surgical Oncology, Gifu University Graduate School of Medicine
Seki, Japan
2019 Gastrointestinal Cancers Symposium News Planning Team

A. William Blackstock, MD, FASCO, American Society of Clinical Oncology (ASCO); Laura Dawson, MD, FRCPC, FASTRO, American Society for Radiation Oncology (ASTRO); Yanghee Woo, MD, FACS, Society of Surgical Oncology (SSO).

View the disclosures for the News Planning Team.

ATTRIBUTION TO THE 2019 GASTROINTESTINAL CANCERS SYMPOSIUM IS REQUESTED IN ALL NEWS COVERAGE.

###

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on Facebook, Twitter, LinkedIn, and YouTube.